refractory/relapsed positive CD19+ B-cell malignant lymphoma
Conditions
Interventions
Experimental group:infuse 2.0x10^6 CAR+ T Cells/kg
Sponsors
Beijing Tongren Hospital Affiliated to Capital Medical University
Eligibility
Sex/Gender
All
Age
15 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Histopathologically diagnosed as CD19-positive B-cell non-Hodgkin's lymphoma; 2. Aged 15-80 years; 3. Meet one of the following three conditions: (1) Patients with relapsed or refractory B-cell lymphoma treated with a standard chemotherapy regimen and a salvage regimen with rituximab or another CD20 antibody drug and at least two chemotherapy regiments appropriate for their disease, one of which should include anthracyclines; Patients maintained or progressed SD(SD duration =12 weeks; 5. Good heart, liver and kidney function: (1) Serum creatinine = 50%, cardiac ultrasound showed centerless effusion; 6. Eastern Oncology Collaborative Group Activity Status Score (EOCG)0-3; 7. Able to understand and voluntarily sign informed consent; If the subject is a child, the guardian will sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating patients; 2. Have uncontrolled infection; 3. Active hepatitis B or C; 4. Patients who had used steroid hormones within 1 week before transfusion; 5. Patients who had used rituximab two weeks before transfusion; 6. Lesions of central nervous system that cannot be controlled by drugs; 7. Hiv-infected patients; 8. Other diseases that may conflict with this clinical study, including cardiovascular, neurological and psychiatric diseases.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CD19+Bcell;Peripheral blood CAR T+ cells; | — |
Secondary
| Measure | Time frame |
|---|---|
| Remission rate of lymphoma; | — |
Countries
China
Contacts
Public ContactWang Liang
Outcome results
None listed